AU690221B2 - Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions - Google Patents

Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions Download PDF

Info

Publication number
AU690221B2
AU690221B2 AU17433/95A AU1743395A AU690221B2 AU 690221 B2 AU690221 B2 AU 690221B2 AU 17433/95 A AU17433/95 A AU 17433/95A AU 1743395 A AU1743395 A AU 1743395A AU 690221 B2 AU690221 B2 AU 690221B2
Authority
AU
Australia
Prior art keywords
dexanabinol
compound
alkyl
compound according
document
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU17433/95A
Other languages
English (en)
Other versions
AU1743395A (en
Inventor
Anat Biegon
Yoel Kloog
Raphael Mechoulam
Emil Pop
Mordechai Sokolovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Pharmos Corp
Original Assignee
Ramot at Tel Aviv University Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Yissum Research Development Co of Hebrew University of Jerusalem, Pharmos Corp filed Critical Ramot at Tel Aviv University Ltd
Publication of AU1743395A publication Critical patent/AU1743395A/en
Application granted granted Critical
Publication of AU690221B2 publication Critical patent/AU690221B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU17433/95A 1994-02-07 1995-02-06 Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions Ceased AU690221B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US192886 1994-02-07
US08/192,886 US5521215A (en) 1989-11-07 1994-02-07 NMDA-blocking pharmaceuticals
PCT/US1995/001470 WO1995020958A1 (en) 1994-02-07 1995-02-06 Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU1743395A AU1743395A (en) 1995-08-21
AU690221B2 true AU690221B2 (en) 1998-04-23

Family

ID=22711431

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17433/95A Ceased AU690221B2 (en) 1994-02-07 1995-02-06 Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

Country Status (10)

Country Link
US (1) US5521215A (enExample)
EP (1) EP0765160B1 (enExample)
JP (1) JPH09511493A (enExample)
AT (1) ATE237324T1 (enExample)
AU (1) AU690221B2 (enExample)
CA (1) CA2183466A1 (enExample)
DE (1) DE69530389T2 (enExample)
IL (1) IL112572A0 (enExample)
SG (1) SG49625A1 (enExample)
WO (1) WO1995020958A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
WO1998013046A1 (en) 1996-09-27 1998-04-02 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
AU743788B2 (en) * 1997-05-07 2002-02-07 Unimed Pharmaceuticals, Inc. Method of improving disturbed behavior and elevating mood in humans
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
US6110139A (en) * 1997-10-21 2000-08-29 Loubser; Paul Gerhard Retrograde perfusion monitoring and control system
WO1999025350A1 (en) * 1997-11-14 1999-05-27 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
EP1071419B1 (en) * 1998-04-21 2007-07-25 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Cannabinoids as antioxidants and neuroprotectants
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
WO2001028329A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Peripheral cannabinoid receptor (cb2) selective ligands
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
CA2411585A1 (en) * 2000-06-22 2001-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US7329651B2 (en) * 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
WO2002060447A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
EP1372638B1 (en) * 2001-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Cannabinoids for the treatment of breathing disorders during sleep
WO2003005960A2 (en) * 2001-07-13 2003-01-23 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
WO2003035005A2 (en) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US7029918B2 (en) * 2002-01-25 2006-04-18 Roche Diagnostics Operations, Inc. Water-soluble derivatives of lipophilic drugs
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
WO2004021974A2 (en) * 2002-09-05 2004-03-18 Pharmos Corporation Non-psychotropic cannabinoids for prevention of cognitive impairment
EP1567513A2 (en) * 2002-12-04 2005-08-31 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical copositions
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
EP2578561A1 (en) * 2005-09-29 2013-04-10 Albany Molecular Research, Inc. Processes for the production of cannabidiol derivatives and intermediates thereof
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
MA40498A (fr) * 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
US20170038184A1 (en) 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
CN110996926A (zh) 2017-07-20 2020-04-10 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于将亲脂性化合物递送进入和/或穿过皮肤的药物膜组合物
CN111278425B (zh) 2017-09-11 2024-06-11 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法
US20200345656A1 (en) 2017-11-29 2020-11-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoids compositions and methods
EP3873436A1 (en) 2018-11-04 2021-09-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Orally administrable cannabinoids-containing compositions and methods
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179517A (en) * 1976-01-12 1979-12-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel tetrahydrocannabinol type compounds
US4876276A (en) * 1986-10-24 1989-10-24 Yissum Research Development Co. Of The Hebrew University Of Jerusalem (3S-4S)-7-hydroxy-Δ6 -tetrahydrocannabinols

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464695A (en) * 1974-06-24 1977-02-16 Smithkline Corp Dibenzo-b,c-pyrans and pharmaceutical compositions thereof
US4133819A (en) * 1977-06-17 1979-01-09 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
US4209520A (en) * 1977-06-17 1980-06-24 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179517A (en) * 1976-01-12 1979-12-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel tetrahydrocannabinol type compounds
US4876276A (en) * 1986-10-24 1989-10-24 Yissum Research Development Co. Of The Hebrew University Of Jerusalem (3S-4S)-7-hydroxy-Δ6 -tetrahydrocannabinols

Also Published As

Publication number Publication date
SG49625A1 (en) 1998-06-15
EP0765160B1 (en) 2003-04-16
ATE237324T1 (de) 2003-05-15
DE69530389T2 (de) 2004-03-25
EP0765160A1 (en) 1997-04-02
DE69530389D1 (de) 2003-05-22
EP0765160A4 (enExample) 1997-04-09
JPH09511493A (ja) 1997-11-18
AU1743395A (en) 1995-08-21
US5521215A (en) 1996-05-28
CA2183466A1 (en) 1995-08-10
IL112572A0 (en) 1995-05-26
WO1995020958A1 (en) 1995-08-10

Similar Documents

Publication Publication Date Title
EP0765160B1 (en) Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US6096740A (en) Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
KR101397510B1 (ko) 플라보노이드 화합물 및 그 용도
US5434295A (en) Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
US4914197A (en) Novel phosphoric diesters
DE69530702T2 (de) Ester und amide von nicht-steroidalen entzündungs-hemmenden carbonsäuren die als anti-oxidantien 5-lipoxygenase-hemmer und nicht-steroidale entzündungs-hemmende mittel verwendet werden können
EP1299374B1 (en) Novel non-psychotropic cannabinoids
AU2003243282B2 (en) Amelioration of the development of cataracts and other opthalmic diseases
DE69512273T2 (de) Amide von mono-und dicarbonsäuren mit glycosaminen, mit selektiver wirkung auf den peripheren cannabinoiden rezeptor
DE68911891T2 (de) Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung.
EP1043322B1 (en) Vitamin e derivatives
CA2599352A1 (en) Novel lipoxygenase inhibitors
CA2559207A1 (en) Salvinorin derivatives and uses thereof
KR20070040326A (ko) 백내장, 황반 변성 및 다른 안과 질환의 개선
JP5484353B2 (ja) 緑内障の治療および予防用の医薬組成物
JPH06234756A (ja) スカベンジャー活性を有し、かつ過酸化および炎症症状を伴う急性および慢性病状に有用なヒドロキシアミンｎ−アシル誘導体
DE69217473T2 (de) Tocopherol-Analoge zum Gewebeschutz
CA2091550A1 (en) New derivatives of physostigmine, their use and pharmaceutical formulations containing them
DE60007168T2 (de) Benzopyranyl-guanidin-derivate, verfahren zu deren herstellung sowie diese enthaltenden pharmazeutische zusammensetzungen
CA2094548A1 (en) Aminoalcohols-n-acylderivatives as therapeutical agents against the neurogenic endoneural oedema developing at the peripheral nerve
US6797721B2 (en) Phorboxazole derivatives for treating cancer
EP0226753A2 (en) Alpha-tocopherol (halo) uridine phosphoric acid diester, salts thereof, and methods for producing the same
EP0215319A2 (en) Gem-dihalo-1,8-diamino-4-aza-octanes
US20160008319A1 (en) Pharmaceutical compositions for inhibiting angiogenesis
JPWO2006132205A1 (ja) ラジカルスカベンジャー及び活性酸素消去剤